Hormone-induced ischemic necrosis of the femoral head is significantly more common in women than in men. Most of them also have underlying diseases, such as whistling disorders, renal insufficiency, and systemic immune disorders. In a foreign cross-sectional study, 10-30% of cases of osteonecrosis were associated with hormone use. In other literature, prospective longitudinal studies have found that osteonecrosis occurs in only 8-10% of patients on hormone therapy. In some diseases, it is difficult to distinguish the effects of corticosteroids on bone from the effects of these underlying diseases. These (underlying diseases) include the absence of mineralization associated with renal failure or liver failure and osteoporosis associated with vascular-related diseases such as systemic lupus erythematosus. The hormone association with osteonecrosis is based on substantial and detailed evidence on the correlation of hormone therapy with osteonecrosis in whistling and rheumatoid diseases. It is also consistent with the fact that patients who have undergone organ transplantation and patients with Gaucher’s disease have a higher incidence of osteonecrosis. The necessary hormone dose to cause osteonecrosis is not known. Doses are also expressed in terms of average daily dose, peak dose, cumulative dose and duration. In some foreign studies of the correlation between hormone dose and osteonecrosis, the average daily dose or peak dose appeared to be more correlated with osteonecrosis relative to the cumulative dose or duration of treatment. Higher doses showed a greater risk even for short applications. Doses of hormones >20 mg per day exhibited a higher risk of osteonecrosis. The risk of osteonecrosis due to hormones is particularly high in patients who have undergone renal transplantation. This may be due to the association with diminished cancellous bone mineralization and structural fragility. A statistical analysis of a group of 22 studies examining the association between hormones and osteonecrosis revealed a 4.6-fold increase in the rate of osteonecrosis when the average daily dose was increased by 10 mg/day.